Metformin pilot RCT tested feasibility of assessing effects on cellular aging and physical performance.
This pilot and feasibility RCT examined whether chronic metformin administration could reduce aging-related biochemical parameters and improve physical performance in elderly participants, as measured by short physical performance battery testing. The authors framed the study as testing potential benefits for cellular longevity and aging markers, but specific outcomes, sample size, and effect sizes were not reported in the provided abstract.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Nov 17, 2022 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Elderly
- Primary outcome
- Physical performance as measured by short physical performance battery test
- Effect size
- —
- Significance
- Not reported
- Journal
- Mayo Clinic
- Published
- Nov 17, 2022
Sources
Primary source
- Mayo Clinic ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.